

Global Database of Cell & Gene Therapy CDMOs

2026-27 Edition

Industry Activity and Consolidation Briefing

20

companies removed after closing,
merging or being absorbed

6

new entries added,
including newly formed CDMOs

124

cell & gene therapy CDMOs
profiled in this edition

Overview

The 2026-27 edition of the BioInformant Global Database of Cell and Gene Therapy CDMOs reflects a year of heavy consolidation in the cell and gene therapy contract manufacturing sector. We removed 20 companies that have closed, merged or been absorbed into other organizations, and added 6 new entries, including newly formed CDMOs such as Rose BioSolutions, Kincellis Advanced Therapies and 3PBIOVIAN.

The database now profiles 124 organizations, and acquisitions, divestitures and rebrands from the past year are reflected throughout. This edition also adds more detail on each company, giving you a fuller picture of who is operating in the market today and who owns them. The database features companies who specialize in manufacturing and clinical trial support specifically for cell and gene therapies (CGT).

This briefing accompanies the database. It summarizes the milestones that have shaped the sector since 2019, highlights the most important themes behind this year's changes, profiles the new entries, and shows where companies that were removed from the database can now be found.

Why CDMO Partnerships Matter

Among cell and gene therapy companies, the pressure for manufacturing innovation and optimization can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise. Benefits of partnering with a cell or gene therapy CDMO include scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies.

In addition to industry giants such as Minaris Advanced Therapies (formed through the merger of Minaris Regenerative Medicine and WuXi Advanced Therapies), Lonza, RoslinCT, and Novo Holdings (which acquired Catalent), the cell and gene therapy marketplace is also supported by a range of specialized CDMOs focused on this sector.

Consolidation at a Glance

Consolidation in Cell & Gene Therapy CDMOs

Key launches, deals and closures, December 2024 – September 2026

20

companies removed after closing, merging or being absorbed

6

new entries added, including newly formed CDMOs

124

cell & gene therapy CDMOs profiled in the 2026-27 edition

NEW & FORMED

Mar 2025	BioCentriq rebrands as Made Scientific
Apr 2025	Artis BioSolutions launches with its Landmark Bio acquisition
May 2025	Minaris Advanced Therapies formed with WuXi AT's US/UK sites
Oct 2025	Mytos launches an automated CDMO
May 2026	Rose BioSolutions formed from Charles River's CGT CDMO
Sep 2026	Kincellis Advanced Therapies formed (Cellipont + Kincell Bio)

ACQUIRED & DIVESTED

Dec 2024	Novo Holdings completes \$16.5B Catalent acquisition
Dec 2024	Ampersand Capital takes control of VIVEbiotech
Feb 2025	Avid Bioservices taken private in a \$1.1B deal
2025	OXB buys a viral vector plant in Durham, NC from Resilience
May 2026	Charles River sells its CGT CDMO and Cell Solutions units to GI Partners
2026	Made Scientific acquires Resilience's East Norriton, PA cell therapy site

CLOSED & EXITING

Apr 2025	AmplifyBio ceases operations
Jun 2025	Resilience winds down six underused sites
Aug 2025	Exothera ceases operations
Jan 2026	Catalent to close its Gosselies, Belgium cell therapy site
May 2026	Takara Bio exits cell therapy contract manufacturing
May 2026	BioNTech to exit its Idar-Oberstein manufacturing site

Source: BioInformant, Global Database of Cell & Gene Therapy CDMOs, 2026-27



Key launches, deals and closures in cell and gene therapy contract manufacturing, December 2024 – September 2026.

CGT CDMO Industry Activity and Consolidation

To understand the changes behind this year's update, here is a look at the major milestones that have shaped the cell and gene therapy CDMO sector in recent years.

Continued in the Full Briefing

The complete industry briefing is included with the paid 2026-27 edition of the Global Database of Cell & Gene Therapy CDMOs. It continues with the full 2019–2026 timeline of launches, deals and closures, the key themes behind this year's changes, profiles of the six new entries, a reference table showing where each of the 20 removed companies can now be found, and guidance on using the database.

Learn more or purchase: bioinformant.com/product/cell-gene-therapy-cdm